Premedication with Intranasal Dexmedetomidine in Sedation of Patients Undergoing Total Knee Arthr… (NCT04859283) | Clinical Trial Compass
CompletedPhase 4
Premedication with Intranasal Dexmedetomidine in Sedation of Patients Undergoing Total Knee Arthroplasty
Finland100 participantsStarted 2022-06-10
Plain-language summary
This study aims to find out if preoperatively given dexmedetomidine is effective analgesic adjuvant for treating postoperative pain in patients undergoing elective total knee arthroplasty (TKA). Another aim is to determine if premedication with intranasal dexmedetomidine could provide sufficient sedation to alleviate anxiety during TKA.
Who can participate
Age range35 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The patient is scheduled for elective unilateral total knee arthroplasty (TKA) under spinal anesthesia
✓. Fluent skills in finnish language (to understand the given information and to be able to give informed consent and communicate with the study personnel)
✓. Age between 35 and 80 years
✓. Weight between 50 and 100 kg
✓. American Society of Anesthesiologists status 1-3
✓. Written informed consent from the patient
Exclusion criteria
✕. A previous history of intolerance to the study drug or related compounds and additives
✕. Disease or condition affecting patient's ability to give written informed consent
✕. Existing or recent disease possible affecting absorption, distribution, metabolism, excretion or response to the study drug
✕. History of severe cardiac disease (valvular insufficiency, severe left ventricular dysfunction) or abnormal ECG rhythm (bradycardia \< 50/min, 2nd or 3rd degree atrioventricular-block, pacemaker)